December 2018—A prospective study in patients with advanced non-small cell lung cancer has demonstrated that the blood-based Guardant360 assay, developed by Guardant Health, identified clinically actionable mutations in nearly twice as many patients as tissue biopsy alone (Aggarwal C, et al. JAMA Oncol. Epub ahead of print Oct. 8, 2018). Additionally, the results suggest a potential clinical strategy for treatment-naïve advanced NSCLC of plasma genotyping first ahead of traditional tissue genotyping.
Guardant Health, 855-698-8887